The use of the complex drug “COLIFLOX® orale” for aeromonosis of carp (Cyprinus carpio) in conditions of cage farming

Abstract

Cage fish farming is accompanied by a high level of organic pollution of the habitat due to high stocking density and intensive feeding. These conditions favor the development of conditionally pathogenic microflora that causes bacterial diseases of fish, which lead to their death, a decrease in growth rates and a violation of the commercial qualities of fish products. Currently, there is no choice of medicines for therapeutic measures for fish bacteriosis, since only one antibacterial drug, Antibac, is allowed for use in aquaculture. In this regard, for the first time, the therapeutic efficacy of a complex medicinal product for veterinary use “COLIFLOX® orale” (manufacturer “AVZ S-P” LLC) based on enrofloxacin and colistin was studied in carp aeromonosis complicated by conditionally pathogenic microflora. For the study, two-year-old carp with an average weight 130±12 g were used, which were kept in the cages of JSC “Biserovsky Fish Processing Plant” (Moscow region). The isolation of pathogens and the determination of their sensitivity to antibacterial drugs were carried out at the FBSI SSC PMB. The experimental and control groups were formed from carp with clinical signs of chronic aeromonosis: focal redness of the skin, scale loss, dark red ulcers located on the sides of the body and caudal stem, partial necrosis of the fins, anal ring hyperemia. During the experiment, it was found that “COLIFLOX ® orale”, used at a dose of 0.2 ml per 1 kg of fish weight for 7 consecutive days with feed, is a reliable and effective remedy for the treatment of mixed bacterial diseases of carp, in which bacteria of the genus Aeromonas play a dominant role.